Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Perflutren-based echocardiographic contrast in patients with right-to-left intracardiac shunts.

Kalra A, Shroff GR, Erlien D, Gilbertson DT, Herzog CA.

JACC Cardiovasc Imaging. 2014 Feb;7(2):206-7. doi: 10.1016/j.jcmg.2013.11.003. No abstract available.

2.

Safety With Echocardiographic Contrast Agents.

Muskula PR, Main ML.

Circ Cardiovasc Imaging. 2017 Apr;10(4). pii: e005459. doi: 10.1161/CIRCIMAGING.116.005459. Review.

3.

Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.

Parker JM, Weller MW, Feinstein LM, Adams RJ, Main ML, Grayburn PA, Cosgrove DO, Goldberg BA, Darge K, Nihoyannopoulos P, Wilson S, Monaghan M, Piscaglia F, Fowlkes B, Mathias W, Moriyasu F, Chammas MC, Greenbaum L, Feinstein SB.

Am J Cardiol. 2013 Oct 1;112(7):1039-45. doi: 10.1016/j.amjcard.2013.05.042. Epub 2013 Jun 28. Review.

PMID:
23816393
4.

Incidence of adverse events associated with use of perflutren contrast agents for echocardiography.

Herzog CA.

JAMA. 2008 May 7;299(17):2023-5. doi: 10.1001/jama.299.17.2023. No abstract available.

PMID:
18460662
5.

Cardiac ultrasound imaging in acute care settings.

Marwick TH, Narula J.

JACC Cardiovasc Imaging. 2010 Jun;3(6):671-2. doi: 10.1016/j.jcmg.2010.04.005. No abstract available.

6.

Assessment of the vascularity of a left ventricular mass using myocardial contrast echocardiography.

Lepper W, Shivalkar B, Rinkevich D, Belcik T, Wei K.

J Am Soc Echocardiogr. 2002 Nov;15(11):1419-22.

PMID:
12415242
7.

Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies.

Kusnetzky LL, Khalid A, Khumri TM, Moe TG, Jones PG, Main ML.

J Am Coll Cardiol. 2008 Apr 29;51(17):1704-6. doi: 10.1016/j.jacc.2008.03.006. Epub 2008 Apr 9.

8.

Ultrasound contrast agent safety: from anecdote to evidence.

Main ML.

JACC Cardiovasc Imaging. 2009 Sep;2(9):1057-9. doi: 10.1016/j.jcmg.2009.05.008. No abstract available.

9.

Ultrasound contrast agents: balancing safety versus efficacy.

Main ML, Goldman JH, Grayburn PA.

Expert Opin Drug Saf. 2009 Jan;8(1):49-56. doi: 10.1517/14740330802658581 . Review.

PMID:
19236217
10.

Hemodynamic instability after receiving intravenous Perflutren for contrast echocardiography in an elderly female.

Blokh I, Ganem A, Bonaros EP, Stephen BD, Steinberg B, Rosen SE.

Echocardiography. 2004 Oct;21(7):613-5.

PMID:
15488089
11.

Does contrast echocardiography induce increases in markers of myocardial necrosis, inflammation and oxidative stress suggesting myocardial injury?

Knebel F, Schimke I, Eddicks S, Walde T, Ziebig R, Schattke S, Baumann G, Borges AC.

Cardiovasc Ultrasound. 2005 Aug 17;3:21.

12.

Identification of cardiac masses and abnormal blood flow patterns with harmonic power Doppler contrast echocardiography.

Bednarz JE, Spencer KT, Weinert L, Sugeng L, Mor-Avi V, Lang RM.

J Am Soc Echocardiogr. 1999 Oct;12(10):871-5.

PMID:
10511659
13.

Safety of contrast-enhanced echocardiography within 24 h after acute myocardial infarction.

Nucifora G, Marsan NA, Siebelink HM, van Werkhoven JM, Schuijf JD, Schalij MJ, Poldermans D, Holman ER, Bax JJ.

Eur J Echocardiogr. 2008 Nov;9(6):816-8. doi: 10.1093/ejechocard/jen167. Epub 2008 Jul 16.

PMID:
18635517
14.

Perflutren-Induced Angioedema.

Gupta A, Harris S, Naina H.

Echocardiography. 2015 Aug;32(8):1329. doi: 10.1111/echo.12971. No abstract available.

PMID:
26192312
15.

Bubbles in Ballooning: Safety and Utility.

Citro R, Lyon AR, Silverio A, Bossone E.

J Am Soc Echocardiogr. 2015 Jul;28(7):845. doi: 10.1016/j.echo.2015.04.013. Epub 2015 May 19. No abstract available.

16.

Real-time, intracardiac, two-dimensional echocardiography: enhanced depth of field with a low-frequency (12.5 mhz) ultrasound catheter.

Pandian NG, Kumar R, Katz SE, Tutor A, Schwartz SL, Weintraub AR, Gillam LD, McKay RG, Konstam MA, Salem DN, et al.

Echocardiography. 1991 Jul;8(4):407-22.

PMID:
10149263
17.

[Current status and indications for contrast echocardiography].

Weihs W, Anelli-Monti B, Picha R, Schuchlenz H, Harb S, Harnoncourt K.

Acta Med Austriaca. 1994;21(3):74-6. German.

PMID:
7701922
18.

Echocardiography contrast for image optimization: beyond confidence, it is a matter of accuracy.

Pellikka PA, Mulvagh SL.

JACC Cardiovasc Imaging. 2008 Mar;1(2):153-5. doi: 10.1016/j.jcmg.2007.11.004. No abstract available.

19.

Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients.

Abdelmoneim SS, Bernier M, Scott CG, Dhoble A, Ness SA, Hagen ME, Moir S, McCully RB, Pellikka PA, Mulvagh SL.

JACC Cardiovasc Imaging. 2009 Sep;2(9):1048-56. doi: 10.1016/j.jcmg.2009.03.020.

20.

Does contrast echocardiography with Optison induce myocardial necrosis in humans?

Borges AC, Walde T, Reibis RK, Grohmann A, Ziebig R, Rutsch W, Schimke I, Baumann G.

J Am Soc Echocardiogr. 2002 Oct;15(10 Pt 1):1080-6.

PMID:
12373250

Supplemental Content

Support Center